Illumina Inc
Change company Symbol lookup
Select an option...
ILMN Illumina Inc
MA Mastercard Inc
WDBG Neuro-Hitech Inc
GLRY Inspire Faithward Mid Cap Momentum ETF
WCC Wesco International Inc
TNP-F Tsakos Energy Navigation Ltd
ANEB Anebulo Pharmaceuticals Inc
NCA Nuveen California Municipal Value Fund
SGOL abrdn Physical Gold Shares ETF
GAB-K Gabelli Equity Trust Inc

Health Care : Life Sciences Tools & Services | Mid Cap Blend
Company profile

Illumina, Inc. is a provider of sequencing- and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated sequencing and microarray systems, consumables, and analysis tools is designed to accelerate and simplify genetic analysis. Its BaseSpace Informatics Suite integrates directly with its sequencing instruments, allowing customers to manage their biological sample and sequencing runs, process and analyze the raw genomic data, and derive results. Its BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously.


Last Trade
0.15 (0.07%)
B/A Size

Market Hours

Closing Price
Day's Change
-3.98 (-1.83%)
Bid close
Ask close
B/A Size
Day's High
Day's Low

10-day average volume:



6 providers
Yesterday's News, March 27, 2023
Illumina launches new software to enable tertiary analysis for oncology applications, and soon rare disease

As demand for clinical next-generation sequencing grows, Illumina Connected Insights enables user to streamline data interpretation and report generation to inform precision care Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and...(PR Newswire)

March 24, 2023
Illumina Issues Statement in Response to Carl Icahn's Letter

Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, issued the following statement in response to a letter from Carl Icahn dated March 24, 2023: Directors and Officers (D&O) insurance and corporate...(PR Newswire)

March 20, 2023
Illumina Underscores Commitment to Shareholder Value and Responds to Carl Icahn's Statements

-- Illumina's plan will maximize shareholder value -- Illumina is engaged with regulators to define GRAIL's path forward as expeditiously as possible -- Icahn's director nominees do not add value to the Board and will damage Illumina's core business (PR Newswire)

March 14, 2023
Illumina launches its first product enabling long- and short-read sequencing on one instrument

Early customer data reinforces accuracy and flexibility of novel long-read technology, unlocking access to challenging, low DNA input samples Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today...(PR Newswire)

March 13, 2023
Illumina Responds to Icahn Partners' Nomination of Directors

Illumina, Inc. (Nasdaq: ILMN),a global leader in DNA sequencing and array-based technologies,confirmed today that it has received notice from Icahn Partners LP and certain of its affiliates of their intention to nominate three candidates—two current...(PR Newswire)

Thinking about trading options or stock in Illumina, NVIDIA, Tesla, Wells Fargo, or Amazon?

InvestorsObserverissues critical PriceWatch Alerts for ILMN, NVDA, TSLA, WFC, and AMZN. Click a link below then choose between in-depth options trade idea report or a stock score...(PR Newswire)

February 27, 2023
Illumina To Webcast Upcoming Investor Conference

Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: -- 43rd Annual Cowen Health Care Conference on March 7, 2023Fireside chat at 6:50am Pacific Time (9:50am Eastern Time) (PR Newswire)

February 23, 2023
John Hancock expands access to Galleri(R), GRAIL's breakthrough cancer screening technology

Carrier previously became the first life insurer to offer access to the Galleri test through a pilot in 2022 TSX/NYSE/PSE: MFC SEHK: 945 Today, John Hancock, a unit of Manulife (NYSE: MFC), announced it will expand access to GRAIL's Galleri(R)...(PR Newswire)

January 10, 2023
Illumina to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 7, 2023

Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the fourth quarter and full year 2022 following the close of market on Tuesday, February 7, 2023. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis...(PR Newswire)

January 09, 2023
Illumina and Nashville Biosciences Announce Sequencing Agreement with Amgen

Whole-genome sequencing of 35,000 de-identified, diverse genomicDNA samples will begin this month Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Nashville Biosciences LLC, a wholly owned subsidiary...(PR Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.